|
1
|
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
|
Diabetes Care
|
2012
|
2.08
|
|
2
|
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
|
Diabetes Care
|
2012
|
1.22
|
|
3
|
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
|
JAMA
|
2007
|
1.14
|
|
4
|
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.92
|
|
5
|
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
|
J Clin Pharmacol
|
2014
|
0.85
|
|
6
|
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
|
Diabetes Care
|
2013
|
0.75
|
|
7
|
Relating glucose clamp profiles to reduction of blood glucose after insulin administration.
|
Diabetes Technol Ther
|
2004
|
0.75
|